RecruitingNot ApplicableNCT07278882

Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL

A Randomized Controlled Trial of Mobile Technology-assisted Outpatient Maintenance Therapy in Children With Acute Lymphoblastic Leukaemia (ALL)


Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Enrollment

100 participants

Start Date

Dec 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To assess the efficacy of using mobile technology to improve the percentage of time wherein drug dosing is within the target range


Eligibility

Max Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study is evaluating whether a mobile app that helps children with leukemia (ALL — acute lymphoblastic leukemia) and their families track daily oral medications and weekly blood test results can be used safely outside the hospital during the maintenance phase of treatment. **You may be eligible if...** - The child was diagnosed with ALL before age 16 - The child or family has already been using the mobile app for at least 3 months and has taken medications correctly more than 90% of the time - The patient or their legal guardian consents to participate **You may NOT be eligible if...** - There are no specific exclusion criteria listed for this study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALHealth monitoring & reminders for a mobile-phone portal for scheduling a telemedicine clinic visit and receive periodic model-phone messages instructing follow-up blood testing and dose adjustment.

Subjects classified as 'Orange Alert' receive mobile-phone alert messages that instruct them to self-adjust dose of oral medication. Subjects classified as 'Red Alert' are directed to a mobile-phone portal for scheduling a telemedicine clinic visit and receive periodic model-phone messages instructing follow-up blood testing and dose adjustment.


Locations(1)

Institute of Hematology & Blood Diseases Hospital

Tianjin, Tianjin Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07278882